small molecule

LYVISPAH

BACLOFEN

Loss of exclusivitySeptember 2041latest FDA-listed patent expiry
CompanySTRIDES PHARMA INTERNATIONAL AG

Drug detail

Brand nameLYVISPAH
Active ingredientBACLOFEN
Strength5MG/PACKET
Dosage formGRANULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2021
Marketing statusDISCN

Listed patents

PatentExpiresType
11850225September 2041product
11491125September 2041product
10792262July 2039product
11654124July 2039product
11931328July 2039product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LYVISPAH patent cliff — loss of exclusivity September 2041 | CliffBio